昭衍新药(603127.SH)：拟与专业投资机构合作参与投资设立基金

Core Viewpoint - Zhaoyan New Drug (603127.SH) is establishing a seed fund in collaboration with investment management firms to focus on strategic emerging industries, particularly in biomedicine and high-end medical devices [1] Group 1 - The company plans to sign a partnership agreement with Yifeng Capital and Yifeng Mingyuan Technology to set up the Shenzhen Yifeng Guangming Science City Seed Fund [1] - The fund will target investments in industries supported by the Shenzhen government, emphasizing biomedicine and high-end medical devices [1] - The company or its designated subsidiary will contribute no more than 10 million RMB as a limited partner in the fund [1]